|
Procedures (mean ± SD)
|
1.8 ± 1.2
|
1.9 ± 1.2
|
|
1 procedure
|
457 (50.8)
|
118(48.3)
|
|
2–3 procedures
|
365 (40.6)
|
103(42.2)
|
|
more than 3 procedures
|
77 (8.6)
|
23(9.4)
|
|
Best tumor response, n (%)
| | |
|
CR
|
18 (2.0)
|
6 (2.5)
|
|
PR
|
203 (22.6)
|
56 (23.0)
|
|
SD
|
259 (28.8)
|
73 (29.9)
|
|
DCR (CR + PR + SD)
|
480 (53.4)
|
135 (55.3)
|
|
Median TTP (95%CI) months
|
5.7(4.7–6.6)
|
7.7 (5.7–9.8)
|
|
Cases of PD, n (%)
|
419 (46.6)
|
109 (44.7)
|
|
Patterns of PD
| | |
|
Enlarged or new lesion (n, %)
|
186 (20.7)
|
49 (20.1)
|
|
Metastasis or vessel invasion (n, %)
|
233 (25.9)
|
60 (24.6)
|
|
Treatment after TACE
| | |
|
Heat ablation (n, %)
|
135 (15.0)
|
43 (17.6)
|
|
Resection (n, %)
|
93 (10.3)
|
27 (11.1)
|
|
Sorafenib (n, %)
|
86 (9.6)
|
21 (8.6)
|
